H.C. Wainwright analyst Edward White maintained a Buy rating on Clovis Oncology (CLVS – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $4.57, close to its 52-week low of $4.06.
According to TipRanks.com, White is a 5-star analyst with an average return of 26.5% and a 44.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.
Currently, the analyst consensus on Clovis Oncology is a Hold with an average price target of $6.00.
Clovis Oncology’s market cap is currently $541.1M and has a P/E ratio of -1.50. The company has a Price to Book ratio of -1.72.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.